May 7, 2021

Xcenda is a key supporter of ISPOR 2021

Join Xcenda at ISPOR 2021 starting on Monday, May 17 through Thursday, May 20. Meet (virtually) with our commercialization and scientific consultants at this year's event where Xcenda is a "key supporter" of the conference.

As leaders in innovation for over 25 years, our creative, scientific minds of Xcenda have been delivering access “firsts”. We proudly launched the first reimbursement field team, developed the first outcomes analyzer, as well as the concept of the product value proposition—all by staying focused on being patient-first. Connect with us at this virtual event and we'll help you effectively navigate today’s complex healthcare landscape and help you deliver the most distinctive body of evidence that demonstrates your value story.

Woman on computer

Start a conversation

Meet with Xcenda

Woman on computer

We’re committed to helping you find solutions to maximize access to your product.  From generating evidence that payers demand to value assessment frameworks consulting, turn to Xcenda for innovative solutions to prove the value of your therapy. 

Meet with Mike Eaddy, Vice President of Scientific Consulting, and Patricia Wolfangel, Vice President of Customer Engagement, to discuss strategies and solutions for your product.

Woman on computer
Werner Kulp

Podium presentation

Patient-Relevance of Endpoints Other Than Overall Survival (non-OS endpoints) in Oncology Health Technology Assessments by the Federal Joint Committee (G-BA) in Germany

Werner Kulp

Authors:

  • Werner Kulp (presenter)
  • Vishwas Agashe
  • Nikolas Couybes
  • Jason Ward
Werner Kulp

Xcenda continues excellence in innovative research

Join us at the ISPOR 2021 virtual conference as we are proud to present the following reach.

Poster title Xcenda authors
Budget Impact of reSET-O With Treatment-as-Usual (TAU) vs TAU Alone For The Treatment of Opioid Use Disorder (OUD) Over 5 Years
Danmeng Huang, Charley Hallock, Lorie Mody
Evaluation of Artificial Intelligence within DistillerSR Software As a Second Reviewer for a Systematic Literature Review Aishani Patel, Charley Hallock, Nicole Fusco, Sarah Cadarette, Lorie Mody
Conceptualization and novel budget impact analysis framework for treatments of myasthenia gravis Danmeng Huang, David Campbell
Current Utilization and Perceptions of Value Assessment Frameworks Among United States Payers
Allie Choate, Annie Yan, Robin Tan, Linnea Tennant
The Evolution of Payer Perceptions of ICER Seth Cook, Anne Loos, Robin Tan, Linnea Tennant
Potential Drug-Drug Interactions to Novel Anti-Androgen Therapies Among Non-Metastatic Castration-Resistant Prostate Cancer Patients
Andrew Gaiser